Hiroshi Nokihara

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Topics

Combination Therapy

Amyotrophic Lateral Sclerosis

Tyrosine Kinase

Top Venues

Thoracic cancer

JMIR research protocols

This page only lists publications with an associated author ORCID identifier.

Publications

Akinari Tsukada, Chie Morita, Yosuke Shimizu, Yukari Uemura, Go Naka, Jin Takasaki, Hiroshi Nokihara, Shinyu Izumi, Masayuki Hojo
Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis. Thoracic cancer 15 (25) (2024)
Akinari Tsukada, Chie Morita, Yosuke Shimizu, Yukari Uemura, Go Naka, Jin Takasaki, Hiroshi Nokihara, Shinyu Izumi, Masayuki Hojo
Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis. Thoracic cancer 15 (25) (2024)
Akinari Tsukada, Chie Morita, Yosuke Shimizu, Yukari Uemura, Go Naka, Jin Takasaki, Hiroshi Nokihara, Shinyu Izumi, Masayuki Hojo
Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis. Thoracic cancer (2024)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer 15 (5) (2023)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer (2023)
Eiji Takeuchi, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara, Yasuhiko Nishioka
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic cancer (2023)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer 15 (5) (2023)
Eiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hiroshi Nokihara, Tsutomu Shinohara, Yasuhiko Nishioka
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic cancer (2023)
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic cancer 15 (5) (2023)
Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Sato, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Shinohara Tsutomu, Yasuhiko Nishioka
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer. Thoracic cancer (2023)
Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Yasuhiko Nishioka
Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease. Thoracic cancer 13 (21) (2022)
Hiroshi Nokihara, Takashi Kijima, Toshihide Yokoyama, Hiroshi Kagamu, Takuji Suzuki, Masahide Mori, Melissa L Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, Kingo Kanda, Machiko Abe, Thomas Burke, Yasushi Goto
Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan. Cancers 14 (12) (2022)
Yutaka Morita, Atsuro Saijo, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yoshimi Bando, Yasuhiko Nishioka
Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer. Thoracic cancer 13 (7) (2022)
Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Akane Abe, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Hisanori Uehara, Yasuhiko Nishioka
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab. Thoracic cancer (2021)
Ryosuke Oki, Yuishin Izumi, Hiroyuki Nodera, Yasutaka Sato, Hiroshi Nokihara, Kazuaki Kanai, Masahiro Sonoo, Makoto Urushitani, Kazuto Nishinaka, Naoki Atsuta, Nobuo Kohara, Toshio Shimizu, Hitoshi Kikuchi, Masaya Oda, Ken Ikeda, Makiko Nagai, Kiyonobu Komai, Yasuhiro Kojima, Daisuke Kuzume, Sagiri Isose, Shun Shimohama, Koji Abe, Hidefumi Ito, Kazuyuki Noda, Tomohiko Ishihara, Mitsuya Morita, Takayoshi Shimohata, Satoshi Teramukai, Tatsuo Kagimura, Kensuke Noma, Hiroaki Yanagawa, Satoshi Kuwabara, Ryuji Kaji, null null
The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial. JMIR research protocols 7 (12) (2018)